Niagen Bioscience (NASDAQ:NAGE – Get Free Report) is one of 55 publicly-traded companies in the “Personal Care Products” industry, but how does it weigh in compared to its competitors? We will compare Niagen Bioscience to related businesses based on the strength of its earnings, risk, analyst recommendations, dividends, institutional ownership, valuation and profitability.
Profitability
This table compares Niagen Bioscience and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 8.37% | 10.18% | 7.57% |
| Niagen Bioscience Competitors | -3.47% | -62.34% | 0.18% |
Institutional & Insider Ownership
15.4% of Niagen Bioscience shares are owned by institutional investors. Comparatively, 48.6% of shares of all “Personal Care Products” companies are owned by institutional investors. 10.0% of Niagen Bioscience shares are owned by company insiders. Comparatively, 11.7% of shares of all “Personal Care Products” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Volatility & Risk
Earnings and Valuation
This table compares Niagen Bioscience and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | $17.38 million | 15.33 |
| Niagen Bioscience Competitors | $7.92 billion | $1.10 billion | 9.50 |
Niagen Bioscience’s competitors have higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a summary of current recommendations and price targets for Niagen Bioscience and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| Niagen Bioscience Competitors | 909 | 2955 | 3669 | 229 | 2.41 |
Niagen Bioscience presently has a consensus price target of $8.50, suggesting a potential upside of 361.96%. As a group, “Personal Care Products” companies have a potential upside of 2.76%. Given Niagen Bioscience’s stronger consensus rating and higher possible upside, equities analysts clearly believe Niagen Bioscience is more favorable than its competitors.
Summary
Niagen Bioscience beats its competitors on 9 of the 13 factors compared.
About Niagen Bioscience
Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
